The Runner Who Passed Every Test He Was Given

2 days ago

9 min read

A man whose heart gave out at forty-two had three pillars in excellent order — and one that nobody had ever looked at.

For busy people, or to tune in when on the move, a Google NotebookLM audio podcast is available as a story beneath.

Arrival

The sound comes first. Not a shout, not a fall — the particular silence that follows when a runner who was there a moment ago is no longer upright. Henry hits the path during a weekend run and the people nearby are already moving before they have processed what they saw.

By the time the paramedics reach him, his heart is in ventricular fibrillation — a rhythm that is not a rhythm, electrical chaos where coordinated contraction should be. The defibrillator fires. One shock, and the trace resolves into something the monitor can work with. He is blue-lighted in.

The catheter laboratory team is scrubbed and waiting on arrival. The paramedics transfer him to the table and withdraw to the control room to hand over and watch through the glass. Radial access — a catheter threaded from the wrist to the coronary ostia, the openings of the vessels that feed the heart itself. Fluoroscopy. The left anterior descending artery, the vessel that supplies the front wall of the left ventricle, is fully occluded. A wire is passed across the lesion. The clot is displaced. A balloon opens the narrowing. A stent holds it. Flow returns.

Henry is in his early forties. He was on a training run. The people watching through the glass know better than to let surprise show on their faces — but some of them feel it.

Who they were

Henry was the kind of person whose cardiovascular health, on first examination, appeared exemplary. He was lean — notably so by any clinical measure. He ran long distances, had done for years, and his legs carried the muscle of someone who had put in the miles consistently rather than intermittently. He was in his early forties and gave no outward indication of a man at acute risk.

His blood pressure, on the occasions it had been checked, was normal. He did not smoke. There was nothing in his build, his fitness level or his presentation that would have prompted a second look from a clinician encountering him in any routine context.

His father had died suddenly at fifty. A cardiac event, though the precise nature was not formally pursued. At the time Henry was young, and the death was mourned and absorbed into family history in the way sudden losses sometimes are — without the clinical follow-through that, in retrospect, it warranted. No one suggested that Henry be tested. No one mentioned a condition called familial hypercholesterolaemia, because no one in the family had yet been given that name.

Henry carried on. He ran further, grew leaner, and by the standards of every visible measure available to him, he was doing everything right. This is not a criticism of him. He was doing everything right — for three of the four things that matter. The fourth was operating silently, as it always does, in a column that had never been opened.

The scorecard

There are four pillars on which cardiovascular risk is built, and the argument of this series is simple: all four must be measured, because any one of them, left unchecked, is sufficient, and you cannot tell from the outside which one it is. The pillars are blood pressure, ApoB and LDL cholesterol, glucose and insulin metabolism, and visceral adipose tissue — the fat stored deep in the abdomen around the organs, which behaves very differently from the fat beneath the skin.

Henry's picture, laid flat, looked like this.

His blood pressure was, on the description, normal — though it was never formally measured in a way that found its way into the record the catheter laboratory team had access to. That is an estimate, not a finding, and the distinction matters. His visceral fat, in a lean endurance runner of his build, was almost certainly low — again, a clinical inference from the description, never a measured waist circumference divided by height, never a number anyone wrote down.

His glucose and insulin metabolism was never assessed at all. That column was not reassuring. It was simply absent.

And his LDL cholesterol — the fourth pillar, the one this case turns on — had been measured by the time he reached the catheter laboratory. It came back at 6.0 mmol/L. In the context of familial hypercholesterolaemia, a condition caused by a defect in the receptor that clears LDL from the circulation, that number was not a surprise to those who now knew to look. It had almost certainly been in that range, or close to it, since his teenage years.

A column nobody measured is not a reassuring column. It is an open question wearing the clothes of a clean result.

The knowable years

The lipid panel that returned 6.0 mmol/L in the catheter laboratory was not a new finding in any meaningful biological sense. It was the first time anyone had looked. The number itself had almost certainly been sitting there since Henry was a teenager — not creeping up with age or weight or changing habits, but fixed by inheritance, by a receptor that could not do what receptors are supposed to do.

What would it have cost to know that earlier? Less than a month of a streaming subscription, if ordered privately online. Nothing at all, if asked for by name at a GP appointment. A lipid panel — total cholesterol, LDL, HDL, triglycerides — is among the most ordinary blood tests in medicine. No specialist referral, no imaging, no preparation beyond a name on a form. In the United Kingdom, a patient can request it by name. In both the UK and the United States, it can be ordered directly, posted to a door, and returned within days.

Henry's father died suddenly at fifty. That death was a signal the system was designed to act on. Cascade testing — the offer of lipid measurement to first-degree relatives after a premature cardiovascular death in the family — exists precisely because familial hypercholesterolaemia runs in straight lines through families. That testing did not reach Henry. That is stated here once, plainly, as context.

But the door was also open from Henry's side, at any point across the decades between his father's death and the morning of his collapse. The test required no gatekeeper. It required only the knowledge that the question was worth asking.

Henry did not have that knowledge. That is why this case is published. The reader, having read this far, does. The question worth asking is: when did you last have your LDL measured? If the answer is never, or not recently, or you are not sure what LDL is — that is where this case hands something across. You measure; then you take the number to someone who can help you read it.

The mechanism

Familial hypercholesterolaemia is not a lifestyle diagnosis. It is a structural defect in the LDL receptor — the molecular gateway that sits on liver cells and pulls LDL particles out of the circulation. In a person with a functioning receptor, LDL is cleared continuously, kept in a range the arterial wall can tolerate. In Henry, that clearance was impaired from birth. The particles accumulated. Not because of what he ate, not because of how he trained, not because of anything he did or did not do — because the receptor could not perform its role.

What accumulates is not LDL itself, precisely, but the ApoB-containing particles that carry it. Each particle that lingers in the circulation is a particle available to cross the arterial endothelium — the thin inner lining of the vessel wall. Once inside, those particles are retained, oxidised, taken up by immune cells, and incorporated into plaques. This is established biology, settled by decades of pathological study and confirmed by Mendelian randomisation — a form of genetic evidence that demonstrates causation rather than association, because the genetic variants that raise LDL from birth are randomly assigned at conception, independent of every other factor.

The plaques that form are not uniformly obstructive. Many remain silent for years, even decades. What makes them dangerous is not only their size but their composition — a lipid-rich core beneath a fibrous cap that can rupture without warning. When a plaque ruptures, the contents contact the blood, a clot forms rapidly, and an artery that was patent one minute can be fully occluded the next.

Henry's three other pillars — blood pressure, glucose metabolism, and visceral fat — were all, on the available evidence, in reasonable order. That matters, because it illustrates something the interactive above is designed to show: sound pillars do not offset a damaged one. Each pillar operates through its own mechanism. A healthy metabolic environment reduces some contributors to plaque vulnerability, and that is not nothing. But it does not correct a receptor defect, does not clear the particles already embedded in the wall, and does not prevent rupture in a plaque that has been accumulating for twenty-five years.

The untaken path

This is not a claim that measurement would have saved Henry. It is a statement of what measurement would have permitted: the years between his father's death and the morning of his collapse, in which an LDL of 6.0 mmol/L could have been identified, and the exposure that would not have accrued had treatment begun.

The exposure arithmetic is not an abstraction. LDL burden is cumulative — the concentration in the blood multiplied by the years it has been there, accruing as particles embed in arterial walls and plaques build and consolidate. At the age of forty-two, Henry's cumulative LDL exposure is estimated at 252 mmol/L-years. An average trajectory across the same lifespan, in a person without familial hypercholesterolaemia, runs to approximately 105 mmol/L-years. Henry's burden was 2.40 times that figure — just over twice the exposure of an average forty-two-year-old, carried in the same number of years because the starting concentration was so much higher, not because he lived differently.

Where clinically indicated, pharmacological treatment — statins, and in some cases additional agents — substantially reduces LDL in familial hypercholesterolaemia. The receptor defect does not respond to diet or training; this is not a failure of discipline but a structural fact. Medication is the corrective, and the earlier it begins, the less exposure accrues. Every decade of treatment from an earlier age is a decade of lower concentration in the arterial wall.

Now for what correction would not have moved. Even with treatment beginning in early adulthood, event risk in familial hypercholesterolaemia is reduced substantially but not to population baseline. The truthful claim is a large shift in probability, not a guaranteed different Saturday morning. And there is a second open question that Henry carries, and that his clinicians now carry with him: his Lp(a) was never measured. Lp(a) is a lipoprotein variant — it sits within the same ApoB column as LDL, but it is genetically fixed, elevated in a meaningful proportion of people with familial hypercholesterolaemia, and not lowered by statins. It is measured once in a lifetime, in nmol/L, and it carries its own independent contribution to arterial risk. Henry's figure is unknown. That means neither he nor anyone treating him knows how much of his residual risk sits outside what his current treatment addresses. That question remains open.

The interactive above carries a control: the age at which LDL was detected. Move it, and watch what changes.

The lesson

Henry was lean, fit, visibly well, and carrying a number that had never been written down. The pillars that could be seen — his body, his pace, his stamina — were sound. The one that could not be seen was the one this case turned on. That is the argument for measuring all four, not the ones that seem most likely to be abnormal, and not the ones most visible to the eye. An unmeasured pillar is not a reassuring pillar. It is a question nobody has yet asked.

My view, and I hold it plainly, is that every adult should know their LDL or ApoB the way they know their blood pressure. That is not the current guideline position — it is where I have arrived, and this case is part of why I am there. You can have your blood pressure checked free at any pharmacy counter, or on a home monitor for less than a month of a streaming service. You can estimate your visceral fat with a tape measure — waist divided by height, a number under 0.5 is where you want to be. You can post an HbA1c to your door. And you can ask for a lipid panel by name, or order one online. These are the four cheapest numbers in medicine, and none of them require anyone's permission.

You measure. If a column is not where it should be, you take the number to your doctor — not to wait for a system to find you, but to walk in with the evidence in hand. That is a different consultation. It is the one Henry never got to have.

Summary

SUMMARY

Henry was lean, fast, and forty-two. His blood pressure was normal, his weight was healthy, and he had run competitively for years. Nothing flagged a problem. Then his heart stopped on a weekend run — because one critical risk factor had never once been measured.

VAT Trap